Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study

被引:18
作者
Vicente, Jorge [1 ]
Gonzalez-Andrade, Fabricio [2 ]
Soriano, Antonia [1 ]
Fanlo, Ana [1 ]
Martinez-Jarreta, Begona [3 ]
Sinues, Blanca [1 ]
机构
[1] Univ Zaragoza, Dept Pharmacol, Zaragoza 50009, Spain
[2] Cent Univ Ecuador, Fac Med Sci, Quito 170136, Ecuador
[3] Univ Zaragoza, Dept Legal Med, Zaragoza 50009, Spain
关键词
CYP2C8; CYP2C9; CYP2C19; Polymorphism; Spaniards; Ecuadorians; PROTON PUMP INHIBITORS; CYTOCHROME P4502C9; CYP2C19-ASTERISK-17; ALLELE; MUTANT ALLELES; METABOLISM; VARIANT; FREQUENCIES; PHARMACOKINETICS; VARIABILITY; CAUCASIANS;
D O I
10.1007/s11033-013-2971-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study was designed to investigate the potential differences between Spaniards and Ecuadorian Mestizo people regarding CYP2C8, CYP2C9, and CYP2C19 genetic polymorphisms. DNA from 282 Spaniard and 297 Ecuadorian subjects were analyzed by either a previously reported pyrosequencing method (CY2C8*3, CYP2C9*2, CYP2C9*3, CYP2C19*2 and CYP2C19*3) or a nested PCR technique (CYP2C19*17). Whereas CYP2C19*17 allele distribution was higher in Ecuadorians than in Spaniards (P < 0.001) and the frequency of CYP2C19*3 was similar in these two populations (P > 0.05), the other allelic variants were detected at significantly lower frequencies in Ecuadorians than in Spaniards (P < 0.05). According to the diplotype distributions, the prevalence of the presumed CYP2C9 and CYP2C8 extensive metabolizers was higher in Ecuadorians than in Spaniards (P < 0.05). Individuals genotyped CYP2C19*1/*17 and *17/*17 who were considered as ultrarapid metabolizers were overrepresented in Ecuadorians in relation to Spaniards (P < 0.001). By contrast, among Ecuadorians no poor metabolizers (PMs) of either CYP2C8 or CYP2C9 were found and only two individuals were CYP2C19 PMs. These data are compatible with a higher CYP2C8, CYP2C9, and CYP2C19 activity in Mestizo Ecuadorians as opposed to Spaniards, which could imply differences in dosage requirements for drugs metabolized by these cytochromes and should also be considered in allele-disease association studies.
引用
收藏
页码:1267 / 1272
页数:6
相关论文
共 45 条
[11]   Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P4502C8 and 2C9 amino acid polymorphisms [J].
García-Martín, E ;
Martínez, C ;
Tabarés, B ;
Frías, J ;
Agúndez, JAG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) :119-127
[12]   Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals [J].
Garcia-Martin, Elena ;
Martinez, Carmen ;
Ladero, Jose M. ;
Agundez, Jose A. G. .
MOLECULAR DIAGNOSIS & THERAPY, 2006, 10 (01) :29-40
[13]  
Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242
[14]   BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY [J].
GOLDSTEIN, JA ;
DEMORAIS, SMF .
PHARMACOGENETICS, 1994, 4 (06) :285-299
[15]   Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations [J].
Goldstein, JA ;
Ishizaki, T ;
Chiba, K ;
deMorais, SMF ;
Bell, D ;
Krahn, PM ;
Evans, DAP .
PHARMACOGENETICS, 1997, 7 (01) :59-64
[16]   Clinical relevance of genetic polymorphisms in the human CYP2C subfamily [J].
Goldstein, JA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) :349-355
[17]   CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population [J].
Hong, XM ;
Zhang, SC ;
Mao, GY ;
Jiang, SQ ;
Zhang, Y ;
Yu, YX ;
Tang, GF ;
Xing, HX ;
Xu, XP .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) :627-634
[18]   MEPHENYTOIN HYDROXYLATION IN THE CUNA AMERINDIANS OF PANAMA [J].
INABA, T ;
JORGE, LF ;
ARIAS, TD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 25 (01) :75-79
[19]   Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects [J].
Ingelman-Sundberg, Magnus ;
Sim, Sarah C. ;
Gomez, Alvin ;
Rodriguez-Antona, Cristina .
PHARMACOLOGY & THERAPEUTICS, 2007, 116 (03) :496-526
[20]  
Isaza Carlos, 2007, BMC Clin Pharmacol, V7, P6, DOI 10.1186/1472-6904-7-6